SCHEMBL6073732

SCHEMBL6073732

CC1CN(c2ccc(Nc3ncc4cc(F)c(NC(=O)NC(C)(C)C)nc4n3)cc2)CC(C)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 0.44
FGFR4 P22455 7/20 0.44
FGFR2 P21802 6/20 0.44
FGFR3 P22607 6/20 0.44
CDK4 P11802 3/20 0.44
CCND1 P24385 3/20 0.44
CCND2 P30279 1/20 0.44
CCND3 P30281 1/20 0.44
CSF1R P07333 1/20 0.44
CCNA2 P20248 2/20 0.43
CDK2 P24941 2/20 0.43
CCNT1 O60563 1/20 0.43
CDK9 P50750 1/20 0.43
SRC P12931 6/20 0.43
PDGFRB P09619 5/20 0.43
PDGFRA P16234 5/20 0.43
BCL6 P41182 1/20 0.40
SYK P43405 1/20 0.39
EGFR P00533 4/20 0.39
ALK Q9UM73 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073724 1.00 FGFR1 (0.44) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073616 0.92 CDK4 (0.47) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073620 0.92 CDK4 (0.47) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073930 0.91 FGFR1 (0.48) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073925 0.91 FGFR1 (0.48) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073945 0.91 CDK4 (0.44) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073948 0.91 CDK4 (0.44) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073424 0.90 FGFR1 (0.47) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073429 0.90 FGFR1 (0.47) FGFR1FGFR4FGFR2FGFR3CDK4
SCHEMBL6073958 0.86 FGFR1 (0.41) FGFR1FGFR4FGFR2FGFR3CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 FGFR1 280/4885FGFR4 478/4885FGFR2 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.